About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
ISSN 0300-9092 (Print)
ISSN 2412-5679 (Online)
About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
Logout
Obstetrics and Gynegology2025№10

Premature ovarian failure: modern and promising approaches to improving ovarian function and overcoming infertility

DOI
https://dx.doi.org/10.18565/aig.2025.263

Dikke G.B., Abusueva Z.A., Alieva N.A., Seydalieva K.L.

1) F.I. Inozemtsev Academy of Medical Education, St. Petersburg, Russia; 2) Dagestan State Medical University, Ministry of Health of Russia, Makhachkala, Russia; 3) Lomonosov Moscow State University, Moscow, Russia

Premature ovarian failure (POF) affects approximately 3.5% of female population. This condition is associated with decreased ovarian reserve, infertility and systemic complications.
Objective: To analyze methods of early diagnosis, modern and promising strategies for the treatment of POF with a focus on restoring ovarian function and overcoming infertility.
Materials and methods: The analysis included systematic reviews, meta-analyses, and randomized controlled trials. A total of 62 studies were analyzed.
Results: FSH (less than 25 IU/ml), AMH, and antral follicle count are used for early diagnosis; however, their prognostic value remains controversial. Inhibin B, insulin-like factor 3 (INSL3), and chronic inflammation markers have been noted as predictors. No biomarkers for POF have been identified. Currently, there are no criteria available for predicting the development and timing of POF. Preventive measures and fertility support methods for women with risk factors for POF include lifestyle modifications (adequate physical activity, smoking cessation, sleep restoration, and a balanced diet), nutritional supplements, antioxidants, and mitochondrial function restoration agents (CoQ10, resveratrol, melatonin). Women at risk for POF, as well as those with the latent form of the disease, are recommended to have their reproductive potential assessed before the onset of the disease and to use ART to obtain and vitrify their own eggs/oocytes or ovarian tissue. Hormone replacement therapy for the prevention of complications and the use of ART to overcome infertility (donor oocytes) are of primary importance in the treatment of the clinical form of POF. Promising approaches to fertility restoration include in vitro follicle activation, the use of stem cells, exosomes, platelet-rich plasma, ovarian tissue transplantation, and bioengineered (artificial) ovaries (their study is currently in the experimental stage).
Conclusion: Prediction of the risk for ovarian function loss and early detection of POF make it possible to take measures for preserving or restoring fertility. Preventive interventions help preserve ovarian reserve and increase the likelihood of restoring ovulation. Fertility preservation is achieved by assisted reproduction (cryopreservation of the woman’s own eggs/oocytes or ovarian tissue), while donor oocytes are used in cases of complete POF. Future research should focus on a more in-depth understanding of the pathogenesis of POF, a clear definition of predictors and their significance, as well as the development of personalized methods for prevention and treatment.

Authors’ contributions: Dikke G.B., Alieva N.A., Seydalieva K.L. – collecting and processing the material, writing the text; Abusueva Z.A. – developing the concept and design of the study; Dikke G.B. – final editing of the article.
Conflicts of interest. Authors declare lack of the possible conflicts of interests.
Funding. None of the authors has a financial interest in the submitted materials or methods. The study was conducted without sponsorship.
For citation: Dikke G.B., Abusueva Z.A., Alieva N.A., Seydalieva K.L. Premature ovarian failure: 
modern and promising approaches to improving ovarian function and overcoming infertility.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2025; (10): 42-52 (in Russian)
https://dx.doi.org/10.18565/aig.2025.263

Keywords

premature ovarian failure
ovarian reserve
anti-Müllerian hormone
antral follicles
ovarian function
infertility
Full text (in Russian)

References

  1. Panay N., Anderson R.A., Bennie A., Cedars M., Davies M., Ee C. et al.; ESHRE, ASRM, CREWHIRL, and IMS Guideline Group on POI. Evidence-based guideline: premature ovarian insufficiency. Hum. Reprod. Open. 2024; 2024(4): hoae065. https://dx.doi.org/10.1093/hropen/hoae065
  2. Li M., Zhu Y., Wei J., Chen L., Chen S., Lai D. The global prevalence of premature ovarian insufficiency: systematic review and meta-analysis. Climacteric. 2023; 26(2): 95-102. https://doi.org/10.1080/13697137.2022.2153033
  3. Federici S., Rossetti R., Moleri S., Munari E.V., Frixou M., Bonomi M. et al. Primary ovarian insufficiency: update on clinical and genetic findings. Front. Endocrinol. (Lausanne). 2024; 15: 1464803. https://dx.doi.org/10.3389/fendo.2024.1464803
  4. Салимова М.Д., Наделяева Я.Г. Преждевременная недостаточность яичников в популяционной выборке женщин Прибайкальского региона: распространённость и возрастные особенности. Acta biomedica scientifica. 2020; 5(6): 37-41. [Salimova M.D., Nadelyaeva Ya.G. Premature ovarian insufficiency in a popular sample of women in the Pribaykalsky region: prevalence and age features. Acta biomedica scientifica. 2020; 5(6): 37-41 (in Russian)]. https://dx.doi.org/10.29413/ABS.2020-5.6.4
  5. Блинов Д.В., Хазан П.Л., Мнацаканьян А.Н., Корабельников Д.И., Сафаров А.Т., Павлова Н.В., Захарова Н.С., Пономарев Д.А., Петренко Д.А. Ранняя менопауза и преждевременная недостаточность яичников: проблемы и перспективы. Акушерство, гинекология и репродукция. 2020; 14(3): 328-45. [Blinov D.V., Khasan P.L., Mnatsakanyan A.N., Korabelnikov D.I., Safarov A.T., Pavlova N.V., Zakharova N.S., Ponomarev D.A., Petrenko D.A. Early menopause and premature ovarian insufficiency: problems and prospects. Obstetrics, Gynecology and Reproduction. 2020; 14(3): 328-45 (in Russian)]. https://dx.doi.org/10.17749/2313-7347/ob.gyn.rep.2020.173
  6. Аверкова В.Г., Юренева С.В. Оценка качества жизни пациенток с преждевременной недостаточностью яичников, принимающих заместительную гормональную терапию. Акушерство и гинекология. 2023; 5: 50-8. [Averkova V.G., Yureneva S.V. Quality of life in patients with premature ovarian insufficiency treated with hormone replacement therapy. Obstetrics and Gynecology. 2023; (5): 50-8 (in Russian)]. https://dx.doi.org/10.18565/aig.2023.16
  7. Blümel J.E., Mezones-Holguín E., Chedraui P., Soto-Becerra P., Arteaga E., Vallejo M.S. Is premature ovarian insufficiency associated with mortality? A three-decade follow-up cohort. Maturitas. 2022; 163: 82-7. https://dx.doi.org/10.1016/j.maturitas.2022.06.002
  8. Armeni E. Diagnostic challenges in suspected premature ovarian insufficiency. Case Rep. Womens Health. 2022; 36: e00453. https://dx.doi.org/10.1016/j.crwh.2022.e00453
  9. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Аменорея и олигоменорея. 2024. 35 с. [Ministry of Health of the Russian Federation. Clinical guidelines. Amenorrhea and oligomenorrhea. 2024. 35 p. (in Russian)].
  10. Гулакова Д.М., Бойматова З.К., Юсуфбекова У.Ю., Махмаджанова М.О., Турсунова Д.Т. Критерии ультразвуковой диагностики преждевременной недостаточности яичников у женщин позднего репродуктивного возраста. Мать и дитя. 2023; 4: 19-24. [Gulakova D.M., Boymatova Z.K., Yusufbekova U.Yu., Makhmadzhanova M.O., Tursunova D.T. Evaluation of the method of ultrasonic examination of premature ovarian failure in women of late reproductive age. Mother and child. 2023; 4: 19-24 (in Russian)].
  11. Дубровина С.О., Александрина А.А. Преждевременная недостаточность яичников: арсенал подходов. Акушерство и гинекология. 2022; 3: 13-20. [Dubrovina S.O., Aleksandrina A.D. Premature ovarian failure: an arsenal of approaches. Obstetrics and Gynecology. 2022; (3): 13-20 (in Russian)]. https://dx.doi.org/10.18565/aig.2022.3.13-20
  12. Чернуха Г.Е., Табеева Г.И., Рштуни С.Д., Машаева Р.И., Черных В.Б., Марченко Л.А. Гены, вовлеченные в развитие преждевременной недостаточности яичников. Акушерство и гинекология. 2021; 11: 71-80 [Chernukha G.E., Tabeeva G.I., Rshtuni S.D., Mashaeva R.I., Chernykh V.B., Marchenko L.A. Genes involved in premature ovarian failure. Obstetrics and Gynecology. 2021; (11): 71-80 (in Russian)]. https://dx.doi.org/10.18565/aig.2021.11.71-80
  13. Рштуни С.Д., Зарецкая Н.В., Кузнецова М.В. Марченко Л.А. Особенности наследования тринуклеотидных CGG повторов в гене FMR1 от женщин с преждевременной недостаточностью яичников: серия случаев. Акушерство и гинекология. 2023; 3: 91-8. [Rshtuni S.D., Zaretskaya N.V., Kuznetsova M.V., Marchenko L.A. FMR1 inherited from women with premature ovarian failure: case series. Obstetrics and Gynecology. 2023; (3): 91-8 (in Russian)]. https://dx.doi.org/10.18565/aig.2022.285
  14. Тарасова А.И., Первушова М.С., Кириленко Я.В., Денисенко М.В., Соснова Е.А. Современные взгляды на проблему преждевременной недостаточности яичников. Архив акушерства и гинекологии им. В.Ф. Снегирева. 2025; 12(2): 162-71. [Tarasova A.I., Pervushova M.S., Kirilenko Ya.V., Denisenko M.V., Sosnova E.A. Modern views on the problem of premature ovarian failure. Archives of obstetrics and gynecology named after V.F. Snegirev. 2025; 12(2): 162-71 (in Russian)]. https://dx.doi.org/10.17816/aog646602
  15. Машаева Р.И., Марченко Л.А., Гус А.И., Костюков К.В. Овариальный возраст – ранний маркер преждевременной недостаточности яичников. Акушерство и гинекология. 2025; 3: 120-7. [Mashaeva R.I., Marchenko L.A., Gus A.I., Kostyukov K.V. Ovarian age – an early marker of premature ovarian insufficiency. Obstetrics and Gynecology. 2025; (3): 120-7 (in Russian)]. https://dx.doi.org/10.18565/aig.2024.271
  16. Jiao X., Meng T., Zhai Y., Zhao L., Luo W., Liu P. et al. Ovarian reserve markers in premature ovarian insufficiency: within different clinical stages and different etiologies. Front. Endocrinol. (Lausanne). 2021; 12: 601752. https://dx.doi.org/10.3389/fendo.2021.601752
  17. Nelson S.M., Davis S.R., Kalantaridou S., Lumsden M.A., Panay N., Anderson R.A. Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review. Hum. Reprod. Update. 2023; 29(3): 327-46. https://doi.org/10.1093/humupd/dmac045
  18. Wang W.Q., Chu G.H., Hou X.X. A comparison of Doppler measures of ovarian blood flow between women with and without ovarian dysfunction and correlations of Doppler indices with ovarian dysfunction markers: a meta-analysis. Ann. Transl. Med. 2023; 11(2): 110. https://dx.doi.org/10.21037/atm-22-5813
  19. Ткаченко Л.В., Гриценко И.А., Тихаева К.Ю., Свиридова Н.И., Гаврилова И.С., Долгова В.А. Оценка факторов риска и прогнозирование преждевременной недостаточности яичников. Акушерство, гинекология и репродукция. 2022; 16(1): 73-80. [Tkachenko L.V., Gritsenko I.A., Tikhaeva K.Yu., Sviridova N.I., Gavrilova I.S., Dolgova V.A. Assessment of risk factors and prediction of premature ovarian failure. Obstetrics, Gynecology and Reproduction. 2022; 16(1): 73-80 (in Russian)]. https://dx.doi.org/10.17749/2313-7347/ob.gyn.rep.2021.273
  20. Barros F., Carvalho F., Barros A., Dória S. Premature ovarian insufficiency: clinical orientations for genetic testing and genetic counseling. Porto Biomed. J. 2020; 5(3): e62. https://dx.doi.org/10.1097/j.pbj.0000000000000062
  21. Moolhuijsen L.M.E., Visser J.A. Anti-müllerian hormone and ovarian reserve: update on assessing ovarian function. J. Clin. Endocrinol. Metab. 2020; 105(11): 3361-73. https://dx.doi.org/10.1210/clinem/dgaa513
  22. Younis J.S., Iskander R., Fauser B.C.J.M., Izhaki I. Does an association exist between menstrual cycle length within the normal range and ovarian reserve biomarkers during the reproductive years? A systematic review and meta-analysis. Hum. Reprod. Update. 2020; 26(6): 904-28. https://dx.doi.org/10.1093/humupd/dmaa013
  23. Tanbo T.G., Fedorcsak P.Z. Can time to menopause be predicted? Acta Obstet. Gynecol. Scand. 2021; 100(11): 1961-8. https://dx.doi.org/10.1111/aogs.14253
  24. Liu Y., Pan Z., Wu Y., Song J., Chen J. Comparison of anti-müllerian hormone and antral follicle count in the prediction of ovarian response: a systematic review and meta-analysis. J. Ovarian. Res. 2023; 16(1): 117. https://dx.doi.org/10.1186/s13048-023-01202-5
  25. Tanaka Y., Hsueh A.J., Kawamura K. Surgical approaches of drug-free in vitro activation and laparoscopic ovarian incision to treat patients with ovarian infertility. Fertil. Steril. 2020; 114(6): 1355-7. https://dx.doi.org/10.1016/j.fertnstert.2020.07.029
  26. Tang M., Sun X., Li P., Deng W., Zhan X., Sun P. et al. IL-33 and soluble ST2 in follicular fluid are associated with premature ovarian insufficiency. Front. Endocrinol. (Lausanne). 2024; 15: 1463371. https://dx.doi.org/10.3389/fendo.2024.1463371
  27. Lin S., Chen S., Zhang Q. Factors influencing premature ovarian insufficiency: a systematic review and meta-analysis. J. Obstet. Gynaecol. 2025; 45(1):2469331. https://dx.doi.org/10.1080/01443615.2025.2469331
  28. Du J., Wang X., Wei M., Huang Q., Bi Y., Huang W. et al. The probability and possible influence factors of intermittent ovarian function recovery in patients with premature ovarian insufficiency. Reprod. Biomed. Online. 2022; 45(6): 1275-83. https://dx.doi.org/10.1016/j.rbmo.2022.07.001
  29. Cui J., Wang Y. Premature ovarian insufficiency: a review on the role of tobacco smoke, its clinical harm, and treatment. J. Ovarian. Res. 2024; 17(1): 8. https://dx.doi.org/10.1186/s13048-023-01330-y
  30. Ates S., Aydın S., Ozcan P., Bakar R.Z., Cetin C. Sleep, depression, anxiety and fatigue in women with premature ovarian insufficiency. J. Psychosom. Obstet. Gynaecol. 2022; 43(4): 482-7. https://dx.doi.org/10.1080/0167482X.2022.2069008
  31. Li J., Huang Y., Xu S., Wang Y. Sleep disturbances and female infertility: a systematic review. BMC Womens Health. 2024; 24(1): 643. https://dx.doi.org/10.1186/s12905-024-03508-y
  32. Muffone A.R.M.C., de Oliveira Lübke P.D.P., Rabito E.I. Mediterranean diet and infertility: a systematic review with meta-analysis of cohort studies. Nutr. Rev. 2023; 81(7): 775-89. https://dx.doi.org/10.1093/nutrit/nuac087
  33. Kadir M., Hood R.B., Mínguez-Alarcón L., Maldonado-Cárceles A.B., Ford J.B., Souter I. et al. Folate intake and ovarian reserve among women attending a fertility center. Fertil. Steril. 2022; 117(1): 171-80. https://dx.doi.org/10.1016/j.fertnstert.2021.09.037
  34. Громова О.А., Андреева Е.Н., Торшин И.Ю., Тапильская Н.И., Уварова Е.В. Системно-биологический анализ ролей марганца в акушерстве и гинекологии: репродуктивное здоровье женщины, регуляция менструального цикла и профилактика пороков развития плода. Вопросы гинекологии, акушерства и перинатологии. 2020; 19(1): 103-13. [Gromova O.A., Andreeva E.N., Torshin I.Yu., Tapil'skaya N.I., Uvarova E.V. A systemic biological analysis of the role of manganese in obstetrics and gynaecology: women’s reproductive health, menstrual cycle regulation and prevention of fetal malformations. Obstetrics, Gynecology and Reproduction. 2020; 19(1): 103-13 (in Russian)]. https://dx.doi.org/10.20953/1726-1678-2020-1-103-113
  35. Karimi E., Arab A., Rafiee M., Amani R. A systematic review and meta-analysis of the association between vitamin D and ovarian reserve. Sci Rep. 2021; 11(1): 16005. https://dx.doi.org/10.1038/s41598-021-95481-x
  36. Bacanakgil B.H., İlhan G., Ohanoğlu K. Effects of vitamin D supplementation on ovarian reserve markers in infertile women with diminished ovarian reserve. Medicine (Baltimore). 2022; 101(6): e28796. https://dx.doi.org/10.1097/MD.0000000000028796
  37. Shi Y.Q., Zhu X.T., Zhang S.N., Ma Y.F., Han Y.H., Jiang Y. et al. Premature ovarian insufficiency: a review on the role of oxidative stress and the application of antioxidants. Front. Endocrinol. (Lausanne). 2023; 14: 1172481. https://dx.doi.org/10.3389/fendo.2023.1172481
  38. Shang Y., Song N., He R., Wu M. Antioxidants and fertility in women with ovarian aging: a systematic review and meta-analysis. Adv. Nutr. 2024; 15(8): 100273. https://doi.org/10.1016/j.advnut.2024.100273
  39. Xiong Y., Si Y., Quan R., Huo X., Chen J., Xu J. et al. hUMSCs restore ovarian function in POI mice by regulating GSK3β-mediated mitochondrial dynamic imbalances in theca cells. Sci. Rep. 2024; 14(1): 19008. https://dx.doi.org/10.1038/s41598-024-69381-9
  40. Ma L., Li X., Li C., Chen P., Lan Y., Huang Y. et al. Association of coenzyme Q10 with premature ovarian insufficiency. Reprod. Sci. 2023; 30(5): 1548-54. https://dx.doi.org/10.1007/s43032-022-01136-1
  41. Florou P., Anagnostis P., Theocharis P., Chourdakis M., Goulis D.G. Does coenzyme Q10 supplementation improve fertility outcomes in women undergoing assisted reproductive technology procedures? A systematic review and meta-analysis of randomized-controlled trials. J. Assist. Reprod. Genet. 2020; 37(10): 2377-87. https://dx.doi.org/10.1007/s10815-020-01906-3
  42. Sah P., Rai A.K., Syiem D. Sirtuin activators as an anti-aging intervention for longevity. Explor. Drug Sci. 2025; 3: 100881. https://dx.doi.org/10.37349/eds.2025.100881
  43. Fiorentino G., Cimadomo D., Innocenti F., Soscia D., Vaiarelli A., Ubaldi F. et al. Biomechanical forces and signals operating in the ovary during folliculogenesis and their dysregulation: implications for fertility. Hum. Reprod. Update. 2023; 29(1): 1-23. https://dx.doi.org/10.1093/humupd/dmac031
  44. Bertoldo A., Pizzol D., Yon D.K., Callegari M., Gobbo V., Cuccurese P. et al. Resveratrol and female fertility: a systematic review. Int. J. Mol. Sci. 2024; 25(23): 12792. https://dx.doi.org/10.3390/ijms252312792
  45. He J., Ye T., Xu K., Liu Y., Ren L. Melatonin: a potential target for regulating ovarian function. Arch. Gynecol. Obstet. 2025; 312(3): 721-31 https://dx.doi.org/10.1007/s00404-025-08079-3
  46. Qi M.K., Sun T.C., Yang L.Y., He J.L., Guo Y.M., Wang H.B. et al. Therapeutic effect of melatonin in premature ovarian insufficiency: Hippo pathway is involved. Oxid. Med. Cell. Longev. 2022; 2022: 3425877. https://dx.doi.org/10.1155/2022/3425877
  47. Pagano E.S., Peña J., Spinedi E. Efficacy of co-adjuvant melatonin and resveratrol chronotherapy for pregnancy achievement in premature ovarian failure (POF). Ann. Clin. Case. Rep. 2023; 8: 2454.
  48. Chaudhri E.N., Salman A., Awartani K., Khan Z., Hashmi S.K. Ovarian tissue cryopreservation versus other fertility techniques for chemoradiation-induced premature ovarian insufficiency in women: a systematic review and future directions. Life. 2024; 14(3): 393. https://dx.doi.org/10.3390/life14030393
  49. Chambon F., Brugnon F., Grèze V., Grémeau A.S., Pereira B., Déchelotte P. et al. Cryopreservation of ovarian tissue in pediatric patients undergoing sterilizing chemotherapy. Hum. Fertil. 2016; 19(1): 23-31. https://dx.doi.org/10.1016/j.jpedsurg.2018.12.021
  50. Dolmans M.M., von Wolff M., Poirot C., Diaz-Garcia C., Cacciottola L., Boissel N. et al. Transplantation of cryopreserved ovarian tissue in a series of 285 women: a review of five leading European centers. Fertil. Steril. 2021; 115(5): 1102-15. https://dx.doi.org/10.1016/j.fertnstert.2021.03.008
  51. Jinno M. Ovarian stimulation by promoting basal follicular growth. Reprod. Biol. Endocrinol. 2025; 23(1): 35. https://dx.doi.org/10.1186/s12958-025-01356-5
  52. Vo K.C.T., Kawamura K. In vitro activation early follicles: from the basic science to the clinical perspectives. Int. J. Mol. Sci. 2021; 22(7): 3785. https://dx.doi.org/10.3390/ijms22073785
  53. Khattak H., Malhas R., Craciunas L., Afifi Y., Amorim C.A., Fishel S. et al. Fresh and cryopreserved ovarian tissue transplantation for preserving reproductive and endocrine function: a systematic review and individual patient data meta-analysis. Hum. Reprod. Update. 2022; 28(3): 400-16. https://dx.doi.org/10.1093/humupd/dmac003
  54. Liu C., Yin H., Jiang H., Du X., Wang C., Liu Y. et al. Extracellular vesicles derived from mesenchymal stem cells recover fertility of premature ovarian insufficiency mice and the effects on their offspring. Cell. Transplant. 2020; 29: 963689720923575. https://dx.doi.org/10.1177/0963689720923575
  55. He J., Ao C., Li M., Deng T., Zheng S., Zhang K. et al. Clusterin-carrying extracellular vesicles derived from human umbilical cord mesenchymal stem cells restore the ovarian function of premature ovarian failure mice through activating the PI3K/AKT pathway. Stem Cell Res. Ther. 2024; 15(1): 300. https://dx.doi.org/10.1186/s13287-024-03926-7
  56. Yang X., Lin T., Luo L., Chen H., Dai Y., Li D. et al. Causal associations between premature ovarian insufficiency and cardiovascular diseases: a mendelian randomization study. Gynecol. Endocrinol. 2025; 41(1): 2487498. https://dx.doi.org/10.1080/09513590.2025.2487498
  57. Hu L., Tan R., He Y., Wang H., Pu D., Wu J. Stem cell therapy for premature ovarian insufficiency: a systematic review and meta-analysis of animal and clinical studies. Arch. Gynecol. Obstet. 2024; 309(2): 457-67. https://dx.doi.org/10.1007/s00404-023-07062-0
  58. Hassan N., Hussein D.M., Malak F.A., Abdelaziz M.A., Boushra M.I., Shaalan W. et al. Mesenchymal stem cells: a therapeutic approach in fertility restoration in premature ovarian insufficiency. Stem Cell Rev. Rep. 2025; 21(7): 2089-2102. https://dx.doi.org/10.1007/s12015-025-10944-2
  59. Moustakli E., Potiris A., Zikopoulos A., Zachariou A., Topis S., Panagopoulos P. et al. Platelet-rich plasma (PRP) in reproductive medicine: a critical review of PRP therapy in low-reserve and premature ovarian insufficiency. Biomedicines. 2025; 13(5): 1257. https://dx.doi.org/10.3390/biomedicines13051257
  60. Vahabi Dastjerdi M., Sheibani S., Taheri M., Hezarcheshmeh F.K., Jahangirian J., Jazayeri M. et al. Efficacy of intra-ovarian injection of autologous platelet-rich plasma in women with poor responders: a systematic review and meta-analysis. Arch. Gynecol. Obstet. 2024; 309(6): 2323-38. https://dx.doi.org/10.1007/s00404-024-07442-0
  61. Diaz A.A., Kubo H., Handa N., Hanna M., Laronda M.M. A systematic review of ovarian tissue transplantation outcomes by ovarian tissue processing size for cryopreservation. Front. Endocrinol. (Lausanne). 2022; 13: 918899. https://dx.doi.org/10.3389/fendo.2022.918899
  62. Buckenmeyer M.J., Sukhwani M., Iftikhar A., Nolfi A.L., Xian Z., Dadi S. et al. A bioengineered in situ ovary (ISO) supports follicle engraftment and live-births post-chemotherapy. J. Tissue Eng. 2023; 14: 20417314231197282. https://dx.doi.org/10.1177/20417314231197282

Received 23.09.2025

Accepted 02.10.2025

About the Authors

Galina B. Dikke, Dr. Med. Sci., Professor, Department of Obstetrics and Gynecology with a Course in Reproductive Medicine, F.I. Inozemtsev Academy of Medical Education, 190013, Russia, Saint Petersburg, Moskovsky Ave., 22, litera M, galadikke@yandex.ru, https://orcid.org/0000-0001-9524-8962
Zukhra A. Abusueva, Dr. Med. Sci., Professor, Department of Obstetrics and Gynecology, Faculty of Medicine, Dagestan State Medical University, Ministry of Health of Russia, 367005, Russia, Makhachkala, Lenin sqr., 1, https://orcid.org/0000-0002-7729-1606
Nuriyana A. Alieva, Dagestan State Medical University, Ministry of Health of Russia, 367005, Russia, Makhachkala, Lenin sqr., 1, https://orcid.org/0009-0008-2114-4640
Kira L. Seydalieva, Lomonosov Moscow State University, 119991, Russia, Moscow, Leninskie Gory str., 1, https://orcid.org/0000-0002-4303-7546
Corresponding author: Galina B. Dikke, galadikke@yandex.ru

Similar Articles

№8 / 2025
Ibragimova U.D., Kozachenko I.F., Adamyan L.V.
Ovarian reserve and surgical hemostasis methods for benign ovarian tumors
№5 / 2025
Turchinets A.I., Badlaeva A.S., Uvarova E.V., Asaturova A.V., Kamaletdinov N.S., Kiseleva I.A., Kumykova Z.Kh., Gavisova A.A.
Association of clinical, laboratory, and morphological characteristics of the ovaries in girls with Turner syndrome and spontaneous puberty
№8 / 2025
Yarmolinskaya M.I., Cherkashina S.A.
Peculiarities of laboratory diagnostics of anti-Müllerian hormone levels
№3 / 2025
Yasnaya D.V., Likhacheva V.V., Proskuryakova L.A., Alontseva V.V., Azarova O.V.
Psychoemotional state of women undergoing in vitro fertilization treatment
№4 / 2025
Saraeva N.V., Tugushev M.T., Shurygina O.V., Montanino Oliva M., Levin V.A., Devyatov I.M.
Experience of myo-inositol use in patients of advanced reproductive age undergoing assisted reproduction
By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.